42.24
Ionis Pharmaceuticals Inc stock is traded at $42.24, with a volume of 887.85K.
It is up +0.23% in the last 24 hours and up +5.61% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$42.15
Open:
$42.34
24h Volume:
887.85K
Relative Volume:
0.53
Market Cap:
$6.72B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-13.90
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
+1.16%
1M Performance:
+5.61%
6M Performance:
+21.57%
1Y Performance:
-18.54%
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IONS
Ionis Pharmaceuticals Inc
|
42.24 | 6.71B | 705.14M | -453.90M | -551.29M | -3.04 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
Apr-07-25 | Initiated | H.C. Wainwright | Buy |
Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
Jul-16-24 | Resumed | Jefferies | Buy |
Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
Sep-29-23 | Initiated | Raymond James | Strong Buy |
Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
Jun-07-23 | Resumed | Piper Sandler | Overweight |
May-04-23 | Upgrade | Citigroup | Sell → Neutral |
Mar-21-23 | Initiated | Bernstein | Underperform |
Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-09-22 | Resumed | Morgan Stanley | Overweight |
Jul-18-22 | Resumed | Oppenheimer | Outperform |
Mar-31-22 | Resumed | Piper Sandler | Overweight |
Mar-01-22 | Initiated | Citigroup | Sell |
Mar-01-22 | Initiated | Guggenheim | Buy |
Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
May-07-21 | Upgrade | UBS | Sell → Neutral |
Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
Dec-16-20 | Initiated | UBS | Sell |
Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
Sep-14-20 | Resumed | JP Morgan | Neutral |
Sep-02-20 | Initiated | The Benchmark Company | Hold |
Jun-01-20 | Resumed | Oppenheimer | Outperform |
May-13-20 | Initiated | RBC Capital Mkts | Outperform |
Mar-05-20 | Initiated | Citigroup | Buy |
Dec-13-19 | Initiated | Oppenheimer | Outperform |
Nov-13-19 | Initiated | BofA/Merrill | Buy |
Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
Aug-08-18 | Reiterated | Stifel | Hold |
Aug-07-18 | Reiterated | Stifel | Hold |
May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
Oct-06-17 | Resumed | Goldman | Sell |
Aug-17-17 | Initiated | Evercore ISI | Outperform |
Aug-09-17 | Reiterated | Stifel | Hold |
Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
Is Ionis Pharmaceuticals Inc. a good long term investmentBreakthrough capital growth - Autocar Professional
TRYNGOLZA Receives EU CHMP Approval Recommendation for Rare Disease FCS Treatment | IONS Stock News - Stock Titan
Ionis Pharmaceuticals Inc. Stock Analysis and ForecastRemarkably fast returns - jammulinksnews.com
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases - MSN
What analysts say about Ionis Pharmaceuticals Inc. stockRapid portfolio appreciation - Autocar Professional
What drives Ionis Pharmaceuticals Inc. stock priceHigh-profit trading signals - jammulinksnews.com
Lou Gehrig’s Disease Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corpo - Barchart.com
Pinning Down Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) P/S Is Difficult Right Now - 富途牛牛
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - GlobeNewswire Inc.
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Ionis HAE drug shows strong results in switch study - Investing.com Australia
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice - Yahoo Finance
Global Motor Neuron Disease Treatment Market to Exhibit Substantial Growth at a CAGR of ~6% by 2032 | DelveInsight - Yahoo Finance
Hutchinson-Gilford Progeria Syndrome Market Driven - openPR.com
(IONS) Technical Data - news.stocktradersdaily.com
Ionis Pharmaceuticals to Host Q2 2025 Earnings Webcast on July 30th - AInvest
Ionis to hold second quarter 2025 financial results webcast - Business Wire
Ionis To Hold Second Quarter 2025 Financial Results Webcast - Barchart.com
Ionis Pharma CEO Monia sells $48,416 in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals CEO Monia Brett Sells 1160 Shares at $41.74 - AInvest
Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Spinocerebellar Ataxias Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc, Biohaven Pharma - Barchart.com
Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT - Insider Monkey
11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds - Insider Monkey
Ionis Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire - MSN
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? - MSN
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN
Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross? - Zacks Investment Research
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up - simplywall.st
Ionis Pharmaceuticals Surges Amid Promising SMA Treatment Progress - StocksToTrade
Ionis Pharmaceuticals Advances as Barclays Upgrades Stock - timothysykes.com
Ionis Pharmaceuticals shares surge 8.89% intraday after Barclays analyst upgrades rating to 'Overweight'. - AInvest
10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know - Nasdaq
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ionis Pharmaceuticals Inc Stock (IONS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
YANG MICHAEL J. | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
6,010 |
WENDER JOSEPH H | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
136,835 |
PARSHALL B LYNNE | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
91,344 |
HERMAN JOAN E | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
46,086 |
Hayden Michael R | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
54,298 |
Diaz Allene M. | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
19,795 |
BERTHELSEN SPENCER R | Director |
Jul 15 '25 |
Option Exercise |
0.00 |
4,079 |
0 |
156,013 |
Monia Brett P | Chief Executive Officer |
Jul 11 '25 |
Sale |
41.74 |
1,160 |
48,416 |
179,820 |
Hayden Michael R | Director |
May 01 '25 |
Buy |
31.86 |
15,000 |
477,900 |
50,219 |
Birchler Brian | EVP, Corp and Development Ops |
Apr 15 '25 |
Option Exercise |
0.00 |
1,875 |
0 |
57,340 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):